EUCTR2004-000039-27-IT进行中（未招募）不适用
A Pivotal Phase 3 Study of MEDI-524 (Numax??), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-ISMedImmune, Inc.5,750
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Classification code 10061603EUCTR2004-000039-27-SEMedImmune, Inc.6,600
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-CZMedImmune, Inc.6,500
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-HUMedImmune, Inc.5,750
进行中（未招募）
不适用
A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.Serious respiratory syncytial virus (RSV) diseaseMedDRA version: 7.0Level: PTClassification code 10061603EUCTR2004-000039-27-ATMedImmune, Inc.6,600